Journal of Surgery Concepts & Practice ›› 2021, Vol. 26 ›› Issue (06): 568-572.doi: 10.16139/j.1007-9610.2021.06.022
• Review • Previous Articles
YANG Zheyu, LU Chenghao, CAl Wei(
)
Received:2020-05-25
Online:2021-11-25
Published:2022-07-27
Contact:
CAl Wei
E-mail:caiwei@shsmu.edu.cn
CLC Number:
YANG Zheyu, LU Chenghao, CAl Wei. Recent advances in study on plasmacyloid dendritic cell and tumor immunity[J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 568-572.
| [1] | Lennert K, Remmele W. Karyometric research on lymph node cells in man. I. Germinoblasts, lymphoblasts & lymphocytes[J]. Acta Haematol, 1958, 19(2):99-113. |
| [2] | O′Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature[J]. Immunology, 1994, 82(3):487-493. |
| [3] | Grouard G, Rissoan MC, Filgueira L, et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand[J]. J Exp Med, 1997, 185(6):1101-1112. |
| [4] | Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood[J]. Science, 1999, 284(5421):1835-1837. |
| [5] | Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type Ⅱ C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction[J]. J Exp Med, 2001, 194(12):1823-1834. |
| [6] | Båve U, Magnusson M, Eloranta ML, et al. FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α-Production induced by apoptotic cells combined with lupus IgG[J]. J Immunol, 2003, 171(6):3296-3302. |
| [7] | Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells[J]. Nat Rev Immunol, 2015, 15(8):471-485. |
| [8] | Shortman K, Sathe P, Vremec D, et al. Plasmacytoid dendritic cell development[J]. Adv Immunol, 2013, 120:105-126. |
| [9] | Rodrigues PF, Alberti-Servera L, Eremin A, et al. Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells[J]. Nat Immunol, 2018, 19(7):711-722. |
| [10] | Schmid M, Kingston D, Boddupalli S, et al. Instructive cytokine signals in dendritic cell lineage commitment[J]. Immunol Rev, 2010, 234(1):32-44. |
| [11] | Waskow C, Liu K, Darrasse-Jèze G, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell develop-ment in peripheral lymphoid tissues[J]. Nat Immunol, 2008, 9(6):676-683. |
| [12] | Koucky V, Bouček J, Fialová A. Immunology of plasmacytoid dendritic cells in solid tumors: a brief review[J]. Cancers (Basel), 2019, 11(4):470. |
| [13] | Seth S, Oberdörfer L, Hyde R, et al. CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions[J]. J Immunol, 2011, 186:3364-3372. |
| [14] | Yu X, Cai B, Wang M, et al. Cross-regulation of two type I interferon signaling pathways in plasmacytoid dendritic cells controls anti-malaria immunity and host mortality[J]. Immunity, 2016, 45(5):1093-1107. |
| [15] | Reizis B. Plasmacytoid dendritic cells: development, re-gulation, and function[J]. Immunity, 2019, 50(1):37-50. |
| [16] | Honda K, Ohba Y, Yanai H, et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-Ⅰ interferon induction[J]. Nature, 2005, 434(7036):1035-1040. |
| [17] | Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases[J]. Nat Rev Immunol, 2008, 8(8):594-606. |
| [18] | Kawasaki T, Kawai T. Toll-like receptor signaling pathways[J]. Front Immunol, 2014, 5:461. |
| [19] | Dasgupta S, Erturk-Hasdemir D, Ochoa-Reparaz J, et al. Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms[J]. Cell Host Microbe, 2014, 15(4):413-423. |
| [20] | Sasai M, Linehan MM, Iwasaki A. Bifurcation of toll-Like receptor 9 signaling by adaptor protein 3[J]. Science, 2010, 329(5998):1530-1534. |
| [21] | Blasius AL, Arnold CN, Georgel P, et al. Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells[J]. Proc Natl Acad Sci U S A, 2010, 107(46):19973-19978. |
| [22] | Saitoh SI, Abe F, Kanno A, et al. TLR7 mediated viral recognition results in focal type I interferon secretion by dendritic cells[J]. Nat Commun, 2017, 8(1):1592. |
| [23] | Tomasello E, Naciri K, Chelbi R, et al. in vivo Molecular dissection of plasmacytoid dendritic cell activation during a viral infection[J]. EMBO J, 2018, 37(19):e98836. |
| [24] | Ito T, Kanzler H, Duramad O, et al. Specialization, kine-tics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells[J]. Blood, 2006, 107(6):2423-2431. |
| [25] | Panda SK, Kolbeck R, Sanjuan MA. Plasmacytoid dendritic cells in autoimmunity[J]. Curr Opin Immunol, 2017, 44:20-25. |
| [26] | Sozzani S, Vermi W, Prete AD, et al. Trafficking properties of plasmacytoid dendritic cells in health and disease[J]. Trends Immunol, 2010, 31(7):270-277. |
| [27] | Guillerey C, Mouries J, Polo G, et al. Pivotal role of plasmacytoid dendritic cells in inflammation and NK-cell responses after TLR9 triggering in mice[J]. Blood, 2012, 120(1):90-99. |
| [28] | Vermi W, Soncini M, Melocchi L, et al. Plasmacytoid dendritic cells and cancer[J]. J Leukoc Biol, 2011, 90(4):681-690. |
| [29] | Han N, Zhang Z, Liu S, et al. Increased tumor-infiltrating plasmacytoid dendritic cells predicts poor prognosis in oral squamous cell carcinoma[J]. Arch Oral Biol, 2017, 78:129-134. |
| [30] | Sisirak V, Faget J, Gobert M, et al. Impaired IFN- production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression[J]. Cancer Research, 2012, 72(20):5188-5197. |
| [31] | Labidi-Galy S, Treilleux I, Goddard-Leon S, et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis[J]. Oncoimmunology, 2012, 1(3):380-382. |
| [32] | Bruchhage K, Heinrichs S, Wollenberg B, et al. IL-10 in the microenvironment of HNSCC inhibits the CpG ODN induced IFN-α secretion of pDCs[J]. Oncol Lett, 2018, 15(3):3985-3990. |
| [33] | Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer[J]. Cancer Research, 2004, 64(16):5535-5538. |
| [34] | Labidi-Galy SI, Sisirak V, Meeus P, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer[J]. Cancer Res, 2011, 71(16):5423-5434. |
| [35] | Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma[J]. Cancer Res, 2005, 65(12):5020-5026. |
| [36] | Conrad C, Gregorio J, Wang YH, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells[J]. Cancer Res, 2012, 72(20):5240-5249. |
| [37] | Huang X, Liu X, Lin X, et al. Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer[J]. Cancer Sci, 2014, 105(2):150-158. |
| [38] | Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, et al. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors[J]. OncoImmunology, 2015, 4(6):e1008355. |
| [39] | Shi W, Li X, Porter JL, et al. Level of plasmacytoid dendritic cells is increased in non-small cell lung carcinoma[J]. Tumor Biol, 2014, 35(3):2247-2252. |
| [40] | Sorrentino R, Morello S, Luciano A, et al. Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma[J]. J Immunol, 2010, 185(8):4641-4650. |
| [41] | Faith A, Peek E, Mcdonald J, et al. Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses[J]. Am J Respir Cell Mol Biol, 2007, 36(3):360-367. |
| [42] | Aspord C, Leccia MT, Charles J, et al. Melanoma hijacks plasmacytoid dendritic cells to promote its own progression[J]. OncoImmunology, 2014, 3(1):e27402. |
| [43] | Aspord C, Leccia MT, Charles J, et al. Plasmacytoid dendritic cells support melanoma progression by promo-ting Th2 and regulatory immunity through OX40L and ICOSL[J]. Cancer Immunol Res, 2013, 1(6):402-415. |
| [44] | Montler R, Bell RB, Thalhofer C, et al. OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer[J]. Clin Transl Immunology, 2016, 5(4):e70. |
| [45] | Schütz C, Inselmann S, Sausslele S, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML[J]. Leukemia, 2017, 31(4):829-836. |
| [46] | Ray A, Das DS, Song Y, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells[J]. Leukemia, 2015, 29(6):1441-1444. |
| [47] | Patsoukis N, Brown J, Petkova V, et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation[J]. Sci Signal, 2012, 5(230):ra46. |
| [48] | Patsoukis N, Bardhan K, Chatterjee P, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation[J]. Nat Commun, 2015, 6:6692. |
| [49] | Weber JS, Yang JC, Atkins MB, et al. Toxicities of immunotherapy for the practitioner[J]. J Clin Oncol, 2015, 33(18):2092-2099. |
| [50] | Zitvogel L, Galluzzi L, Kepp O, et al. Type I interferons in anticancer immunity[J]. Nat Rev Immunol, 2015, 15(7):405-414. |
| [51] | Wolchok JD. PD-1 blockers[J]. Cell, 2015, 162(5):937. |
| [52] | Zheng J, Chan PL, Liu Y, et al. ICOS regulates the ge-neration and function of human CD4+ Treg in a CTLA-4 dependent manner[J]. PloS One, 2013, 8(12):e82203. |
| [53] | Huang J, Liu F, Liu Z, et al. Immune checkpoint in glioblastoma: promising and challenging[J]. Front Pharmacol, 2017, 8:242. |
| [54] | Gil M, Komorowski MP, Seshadri M, et al. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells[J]. J Immunol, 2014, 193(10):5327-5337. |
| [55] | Filley AC, Dey M. Dendritic cell based vaccination stra-tegy: an evolving paradigm[J]. J Neurooncol, 2017, 133(2):223-235. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
